Develops genome-edited, off-the-shelf CAR-T cell therapies for people with blood cancers, using its chRDNA technology to modify donor cells.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) genome-editing biopharmaceutical company…View ↗
Our allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”) -T (“CAR-T”) cell therapy product candidates are manufactured in…View ↗
We are advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic…View ↗
Partners pay for licenses to Caribou's genome-editing technology, related research and development work, and collaboration services. Payments may include upfront and annual fees, milestone payments and royalties on sales; license fees may be paid when the license is transferred, while combined work may be paid over time.
10-K for FY2025, filed Mar 5, 2026To date, all of our revenue consists of licensing and collaboration revenue earned from collaboration and/or licensing agreements entered…View ↗
Our revenues are primarily derived through license and/or license and collaboration agreements. The terms of these types of agreements may…View ↗
If a license to intellectual property controlled by us is determined to be distinct from the other performance obligations identified in…View ↗
Certain of our license agreements include contingent milestone payments. Such milestone payments are typically payable when the…View ↗
Our license and/or collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based…View ↗
$11.2M
10-K for FY2025, filed Mar 5, 2026
$11.2M ↗
Biopharmaceutical partners license Caribou's intellectual property and may work with the company on research and development and collaboration activities.
10-K for FY2025, filed Mar 5, 2026
No. It lost $148.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$26.6MView ↗
8-K, filed Jun 11, 2026
On June 11, 2026, the Company announced long-term follow-up data from its ANTLER phase 1 clinical trial that evaluated vispa-cel, an…View ↗
8-K, filed Mar 31, 2026
On March 31, 2026, Caribou Biosciences, Inc. (the “Company”) issued a press release announcing that it received Regenerative Medicine…View ↗
Growing. Revenue grew 16% in 4 years, from $9.6M in FY2021 to $11.2M in FY2025, about 4% a year.
Narrowed therapy pipeline
The older report described CAR-T and CAR-NK programs, including programs for solid tumors and work developing therapies for AbbVie. The latest report focuses on two clinical-stage allogeneic CAR-T candidates for blood cancers.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 5, 2026Our pipeline includes allogeneic cell therapies from our CAR-T and CAR-NK platforms. We currently are advancing four wholly owned programs…View ↗
Additionally, we are developing allogeneic CAR-NK cell therapies derived from genome-edited induced pluripotent stem cells (“iPSCs”) for…View ↗
In February 2021, we entered into a Collaboration and License Agreement (as amended, the “AbbVie Agreement”) with AbbVie to develop two…View ↗
We are advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic…View ↗
We are focused on the development of our pipeline of allogeneic CAR-T cell therapies. We are advancing two clinical-stage allogeneic CAR-T…View ↗
Our mission is to develop innovative, transformative therapies for patients with devastating diseases through the use of our novel chRDNA…View ↗
Competes with Novartis, Kite Pharma, Bristol-Myers Squibb, Legend Biotech, Allogene Therapeutics, Atara Biotherapeutics, Cellectis, CRISPR Therapeutics, Fate Therapeutics, AbbVie, Arbor Biotechnologies, Beam Therapeutics, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, Metagenomi Therapeutics, Scribe Therapeutics, Precision BioSciences, Prime Medicine, and Sangamo Therapeutics
10-K for FY2025, filed Mar 5, 2026Autologous T cell therapy: Autologous T cell therapies directed at CD19 have been commercialized by Novartis AG (Kymriah®), Kite Pharma…View ↗
Loading...